Analytical and Clinical Performance of the Lumipulse <sup>®</sup> <i>G</i> GFAP Assay in CSF samples
This study demonstrates that the Lumipulse G GFAP assay, when applied to CSF samples, can potentially differentiate AD from non-AD cases. These findings suggest that GFAP can be a valuable biomarker for AD, providing additional diagnostic information alongside traditional biomarkers such as Aβ40, Aβ42 and pTau181. However, since GFAP may also be elevated in other neurological disorders beyond AD, further investigation into these conditions is required.
Authors
- Katsumi Aoyagi (ORCID: https://orcid.org/0000-0003-3818-7985)
- Hisashi Nojima (ORCID: https://orcid.org/0000-0002-8907-5767)
- Jo Kamada
- Mai Yamamoto
- Tomohiro Hamanaka
Institutions
- Fujirebio (Japan) (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_096797
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00